Didier Meseure
Overview
Explore the profile of Didier Meseure including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
1538
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Grandal B, Mangiardi-Veltin M, Laas E, Lae M, Meseure D, Bataillon G, et al.
Cancers (Basel)
. 2021 Mar;
13(4).
PMID: 33670162
The consequences of neoadjuvant chemotherapy (NAC) for PD-L1 activity in triple-negative breast cancers (TNBC) are not well-understood. This is an important issue as PD-LI might act as a biomarker for...
22.
Floris G, Richard F, Hamy A, Jongen L, Wildiers H, Ardui J, et al.
J Natl Cancer Inst
. 2020 Nov;
113(2):146-153.
PMID: 33152071
Background: High levels of stromal tumor-infiltrating lymphocytes (sTIL) are associated with increased pathological complete response (pCR) rate and longer survival after neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) patients. Here,...
23.
Meseure D, Vacher S, Boudjemaa S, Lae M, Nicolas A, Leclere R, et al.
Cancers (Basel)
. 2020 Oct;
12(10).
PMID: 33008024
The PIWI proteins emerging in the development of human cancers, edify PIWI-piRNA ribonucleoproteic complexes acting as pivotal regulators of genome integrity, differentiation and homeostasis. The aim of this study is...
24.
Montaudon E, Nikitorowicz-Buniak J, Sourd L, Morisset L, El Botty R, Huguet L, et al.
Nat Commun
. 2020 Aug;
11(1):4053.
PMID: 32792481
A significant proportion of patients with oestrogen receptor (ER) positive breast cancers (BC) develop resistance to endocrine treatments (ET) and relapse with metastatic disease. Here we perform whole exome sequencing...
25.
Gonzalo Nunez N, Tosello Boari J, Ramos R, Richer W, Cagnard N, Anderfuhren C, et al.
Nat Commun
. 2020 Jul;
11(1):3272.
PMID: 32601304
Tumor-draining lymph node (TDLN) invasion by metastatic cells in breast cancer correlates with poor prognosis and is associated with local immunosuppression, which can be partly mediated by regulatory T cells...
26.
Meseure D, Alsibai K, Vacher S, Hatem R, Nicolas A, Callens C, et al.
Anal Cell Pathol (Amst)
. 2020 May;
2020:9268236.
PMID: 32377505
Epidermal growth factor receptor (EGFR) signalling is a highly regulated process with a tight balance between receptor activation and inactivation in invasive breast carcinomas (IBCs) particularly in triple-negative carcinomas (TNC)....
27.
Zajac O, Leclere R, Nicolas A, Meseure D, Marchio C, Vincent-Salomon A, et al.
Cells
. 2020 Jan;
9(1).
PMID: 31963783
Triple-negative breast cancer (TNBC) is an aggressive form of breast cancer with high risk of relapse and metastasis. TNBC is a heterogeneous disease comprising different molecular subtypes including those with...
28.
Lecerf C, Kamal M, Vacher S, Chemlali W, Schnitzler A, Morel C, et al.
Eur J Cancer
. 2019 Oct;
121:210-223.
PMID: 31593831
Background: Nivolumab and pembrolizumab targeting programmed cell death protein 1 (PD-1) have recently been approved among patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) who failed...
29.
Alsibai K, Vacher S, Meseure D, Nicolas A, Lae M, Schnitzler A, et al.
Noncoding RNA
. 2019 Aug;
5(3).
PMID: 31438464
The gene, also called , is located at the human locus at 9p21.3 and transcribed by RNA polymerase II into a long non-coding RNA of 3834 bp. The gene overlaps...
30.
De Koning L, Decaudin D, El Botty R, Nicolas A, Carita G, Schuller M, et al.
Cancers (Basel)
. 2019 Jun;
11(6).
PMID: 31146482
Uveal melanoma (UM) remains without effective therapy at the metastatic stage, which is associated with (BRCA1 associated protein) mutations. However, no data on DNA repair capacities in UM are available....